Latest market price
535.88
-6.30-1.16%
Analyst
Down 1.2% — Jefferies upgraded to Buy, price target $620.
High confidence
TA
Loading chart...
Snapshot
| Index | — | P/E | 25.93 | EPS (ttm) | 20.91 | Insider Own | 5.82% | Shs Outstand | 13.07M | Perf Week | 5.71% |
| Market Cap | 7.09B | Forward P/E | 19.47 | EPS next Y | 27.85 | Insider Trans | -1.46% | Shs Float | 12.82M | Perf Month | 6.83% |
| Enterprise Value | 7.39B | PEG | 2.89 | EPS next Q | 7.35 | Short Float | 5.35% | Perf Quarter | 0.46% | ||
| Income | 283.00M | P/S | 2.66 | EPS this Y | 16.35% | Short Ratio | 4.33 | Perf Half Y | 27.30% | ||
| Sales | 2.66B | P/B | 8.23 | EPS next Y | 8.05% | ROA | 16.43% | Short Interest | 685.97K | Perf YTD | 26.72% |
| Book/sh | 65.88 | P/C | 147.63 | EPS next 5Y | 8.96% | ROE | 32.10% | 52W High | 562.24 -4.69% | Perf Year | 19.31% |
| Cash/sh | 3.67 | P/FCF | 24.02 | EPS past 3/5Y | 3.67% -1.11% | ROIC | 19.17% | 52W Low | 365.21 46.73% | Perf 3Y | -2.18% |
| Dividend Est. | 2.80 (0.52%) | EV/EBITDA | 16.61 | Sales past 3/5Y | 5.82% 3.99% | Gross Margin | 31.65% | Volatility | 3.61% 2.44% | Perf 5Y | 23.09% |
| Dividend TTM | 2.50 (0.47%) | EV/Sales | 2.78 | EPS Y/Y TTM | 10.58% | Oper. Margin | 13.94% | ATR (14) | 15.02 | Perf 10Y | 288.30% |
| Dividend Ex-Date | Aug 17, 2026 | Quick Ratio | 1.08 | Sales Y/Y TTM | 5.14% | Profit Margin | 10.61% | RSI (14) | 65.05 | Recom | 2.50 |
| Dividend Gr. 3/5Y | 14.13% 10.76% | Current Ratio | 1.11 | EPS Q/Q | 28.08% | SMA20 | 5.33% | Beta | 0.49 | Target Price | 635.00 |
| Payout | 11.94% | Debt/Eq | 0.41 | Sales Q/Q | 10.56% | SMA50 | 5.33% | Rel Volume | 0.83 | Prev Close | 542.18 |
| Employees | 15,811 | LT Debt/Eq | 0.41 | Earnings | Feb 24 | SMA200 | 17.06% | Avg Volume | 151.25K | Price | 535.88 |
| IPO Date | May 03, 1973 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 4.89% 0.86% | Net Debt/EBITDA | 0.68 | Volume | 125,202 | Change | -1.16% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-28-26 | Upgrade | Jefferies | Hold → Buy | $475 → $620 |
| Sep-25-26 | Initiated | UBS | Buy | $650 |
| Feb-27-26 | Downgrade | RBC Capital | Outperform → Sector Perform | |
| Jan-22-26 | Downgrade | Jefferies | Buy → Hold | $550 → $475 |
| Sep-02-25 | Upgrade | Jefferies | Hold → Buy | $550 |
| Nov-05-24 | Reiterated | RBC Capital | Outperform | $697 → $633 |
| May-21-24 | Reiterated | RBC Capital | Outperform | $592 → $697 |
| Apr-28-22 | Reiterated | RBC Capital | Outperform | $592 |
| Mar-11-20 | Upgrade | RBC Capital | Sector Perform → Outperform | |
| Nov-01-19 | Upgrade | JMP Securities | Market Perform → Market Outperform |
Latest News· Times ET
Nov-02-26
09:00AM
Oct-29-26
Oct-28-26
Oct-27-26
04:57PM
04:15PM
Chemed Reports Third-Quarter 2026 Resultsglobenewswire.com
Oct-20-26
Oct-19-26
Oct-13-26
Oct-13-2606:15AM
Oct-09-26
Oct-01-26
Oct-01-2609:00AM
Sep-26-26
Sep-23-26
Sep-23-2605:34AM
Company
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, doctors, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates through two segments: VITAS and Roto-Rooter segments. The company offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees. The company also provides direct medical services to patients, as well as spiritual and emotional counseling to both patients and their families. Chemed Corporation was incorporated in 1970 and is headquartered in Cincinnati, Ohio.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 2,661 | 2,530 | 2,431 | 2,264 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 1,819 | 1,772 | 1,577 | 1,466 | — | — | — | — | — | |
| Gross Profit | 842 | 758 | 854 | 799 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 446 | 417 | 424 | 395 | — | — | — | — | — | |
| Research and Development | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Other Operating Expense | 26 | 0 | 64 | 63 | — | — | — | — | — | |
| Operating Income | 371 | 338 | 366 | 341 | — | — | — | — | — | |
| Interest Expense | 6 | 2 | 2 | 3 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 16 | 19 | 35 | 13 | — | — | — | — | — | |
| Net Income Before Taxes | 382 | 356 | 399 | 350 | — | — | — | — | — | |
| Income Taxes | 101 | 91 | 97 | 78 | — | — | — | — | — | |
| Consolidated Net Income | 283 | 265 | 302 | 273 | — | — | — | — | — | |
| Net Income From Continuing Operations | 283 | 265 | 302 | 273 | — | — | — | — | — | |
| Net Income | 283 | 265 | 302 | 273 | — | — | — | — | — | |
| EPS (Recurring) | 20.95 | 18.42 | 20.10 | 18.11 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 20.95 | 18.42 | 20.10 | 18.11 | — | — | — | — | — | |
| EPS (Diluted) | 20.91 | 18.42 | 19.89 | 17.93 | — | — | — | — | — | |
| EBITDA | 445 | 422 | 464 | 414 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 25.63 | 23.23 | 26.64 | 32.61 | — | — | — | — | — | |
| Price To Sales Ratio | 2.62 | 2.37 | 3.27 | 3.87 | — | — | — | — | — | |
| Gross Margin | 31.64 | 29.96 | 35.13 | 35.29 | — | — | — | — | — | |
| Operating Margin | 13.94 | 13.36 | 15.06 | 15.06 | — | — | — | — | — | |
| Net Margin | 10.64 | 10.47 | 12.42 | 12.06 | — | — | — | — | — | |
| Shares Outstanding | 13 | 14 | 15 | 15 | — | — | — | — | — | |
| Market Capitalization | 6,966 | 5,990 | 7,947 | 8,771 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| LEE SPENCER S | executive vice president | Sep 30 '26 | Option Exercise | 445.35 | 12,099 | 5,388,290 | 26,011 | Oct 01 |
| MCNAMARA KEVIN J | president and CEO | Sep 28 '26 | Sale | 513.45 | 2,000 | 1,026,900 | 66,418 | Sep 30 |
| HUTTON THOMAS C | vice president | Sep 28 '26 | Option Exercise | 445.35 | 4,629 | 2,061,525 | 37,110 | Sep 29 |
| MCNAMARA KEVIN J | president and CEO | Sep 18 '26 | Sale | 501.40 | 2,000 | 1,002,800 | 68,418 | Sep 21 |
| LEE SPENCER S | executive vice president | Aug 21 '26 | Sale | 541.04 | 1,000 | 541,040 | 13,912 | Aug 24 |
| MCNAMARA KEVIN J | president and CEO | Aug 21 '26 | Sale | 541.16 | 2,000 | 1,082,320 | 70,418 | Aug 24 |
| Judkins Brian C | VP and Chief Legal Officer | Aug 10 '26 | Option Exercise | 445.35 | 6,786 | 3,022,145 | 9,222 | Aug 10 |
| Wherley Joel L | CEO - Vitas Healthcare | Aug 05 '26 | Option Exercise | 445.35 | 2,599 | 1,157,465 | 3,451 | Aug 06 |
| MCNAMARA KEVIN J | president and CEO | Aug 03 '26 | Option Exercise | 445.35 | 2,001 | 891,145 | 264,158 | Aug 04 |
| MCNAMARA KEVIN J | president and CEO | Aug 03 '26 | Sale | 539.51 | 2,000 | 1,079,020 | 70,418 | Aug 04 |
| MCNAMARA KEVIN J | president and CEO | Jul 31 '26 | Option Exercise | 445.35 | 2,001 | 891,145 | 92,220 | Aug 04 |
| GRACE PATRICK P | Director | Jul 31 '26 | Sale | 532.00 | 190 | 101,080 | 3,533 | Aug 03 |
| LINDELL ANDREA R | Director | Jun 09 '26 | Sale | 447.33 | 1,347 | 602,554 | 4,578 | Jun 10 |
| WALSH GEORGE J III | Director | May 29 '26 | Sale | 437.83 | 500 | 218,915 | 3,209 | May 29 |
| GRACE PATRICK P | Director | May 08 '26 | Sale | 425.78 | 60 | 25,547 | 3,337 | May 08 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.